Extract
Recent prospective clinical trials have shown antifibrotic therapies slow lung function decline in patients with idiopathic pulmonary fibrosis (IPF) [1, 2] and progressive fibrosing interstitial lung disease (ILD). Similar findings were demonstrated in scleroderma-associated ILD [3], despite use of the immunosuppressive therapy mycophenolate mofetil (MMF). Prospective data for the treatment of other forms of ILD, such as chronic hypersensitivity pneumonitis (CHP) are lacking. Our groups previously reported that the treatment of CHP with MMF was associated with a decreased incidence of adverse events, a reduction in prednisone dose, and improved lung function when compared to prednisone alone [4, 5], but prospective studies are needed to confirm these findings.
Abstract
Patients with chronic hypersensitivity pneumonitis and telomere lengths above the first quartile may have improved survival with mycophenolate therapy. https://bit.ly/3maRXih
Footnotes
Author contributions: Conception and design: A. Adegunsoye, J. Morisset, J.M. Oldham and B. Ley; acquisition of data for the work: A. Adegunsoye, J. Morisset, C.A. Newton, E. Vittinghoff, A.L. Linderholm, P.J. Wolters, M.E. Strek, I. Noth, C.K. Garcia, J.M. Oldham and B. Ley; analysis and interpretation: A. Adegunsoye, J. Morisset, C.A. Newton, E. Vittinghoff, J.M. Oldham and B. Ley; drafting the manuscript for important intellectual content: A. Adegunsoye, J. Morisset, C.A. Newton, E. Vittinghoff, A.L. Linderholm, P.J. Wolters, M.E. Strek, I. Noth, C.K. Garcia, J.M. Oldham and B. Ley; critical revision for important intellectual content: all authors (A. Adegunsoye, J. Morisset, C.A. Newton, E. Vittinghoff, A.L. Linderholm, P.J. Wolters, M.E. Strek, I. Noth, C.K. Garcia, J.M. Oldham and B. Ley); final approval of the submitted manuscript and accountability for all aspects of the work: all authors (A. Adegunsoye, J. Morisset, C.A. Newton, E. Vittinghoff, A.L. Linderholm, P.J. Wolters, M.E. Strek, I. Noth, C.K. Garcia, J.M. Oldham and B. Ley).
Conflict of interest: A. Adegunsoye reports personal fees from Genentech and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: J. Morisset has nothing to disclose.
Conflict of interest: C.A. Newton has nothing to disclose.
Conflict of interest: J.M. Oldham reports personal fees from Boehringer Ingelheim and Genentech, outside the submitted work.
Conflict of interest: E. Vittinghoff has nothing to disclose.
Conflict of interest: A.L. Linderholm has nothing to disclose.
Conflict of interest: M.E. Strek reports grants from Boehringer Ingelheim, Galapagos and Novartis, outside the submitted work.
Conflict of interest: I. Noth reports grants and personal fees from Boehringer Ingelheim (advisory boards), and personal fees from Intermune (advisory boards), Anthera (advisory boards), GSK (speaking honoraria) and Immuneworks (consulting fees), outside the submitted work.
Conflict of interest: C.K. Garcia has nothing to disclose.
Conflict of interest: P.J. Wolters reports grants and personal fees from Boehringer Ingelheim, personal fees from Blade therapeutics and Roche, and grants from Genentech, outside the submitted work.
Conflict of interest: B. Ley reports grants from Nina Ireland Program for Lung Health, during the conduct of the study; personal fees from Genentech, outside the submitted work.
Support statement: NIH K23HL146942, NIH K23HL138190, NIH K23HL148498, NIH R01HL130796, NIH R01 HL093096, NIH KL2TR001870, and Nina Ireland Program for Lung Health. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received July 22, 2020.
- Accepted October 17, 2020.
- Copyright ©ERS 2021